Ana Souto-García1, Ana Fernández-Somoano1, Teresa Pascual2, Sara M Álvarez-Avellón1, Adonina Tardón1. 1. Molecular Epidemiolgy of Cancer Unit, University Institute of Oncology, University of Oviedo, Oviedo, Asturias, Spain; Consortium for Research in Epidemiology and Public Health (CIBERESP), Spain. 2. Pneumology Department, Cabueñes Hospital, Gijón, Asturias, Spain.
Abstract
BACKGROUND: The aim of this study was to investigate how Ser31Arg polymorphisms in p21 may modify lung cancer susceptibility. Because p21 is the major downstream mediator of p53, we analyzed the combined effect of two polymorphisms, p21 Ser31Arg and TP53 Arg72Pro, to elucidate whether polymorphic variants determine the risk of lung cancer. METHODS: This was designed as a hospital-based case-control study, and included 675 cases and 675 control subjects matched by ethnicity, gender, and age. Genotypes were determined by polymerase chain reaction restriction fragment length polymorphism, and multivariate unconditional logistic regression was performed to analyze the results. RESULTS: Subjects who carried the p21 Ser31Arg allele had a higher risk of lung cancer (adjusted odds ratio [OR] 1.38; 95% confidence interval [CI] 0.99-2.03). This risk was increased in men aged younger than 55 years (adjusted OR 2.35; 95% CI 1.00-5.51). Smokers had an increased risk of lung cancer (adjusted OR 2.23; 95% CI 1.24-4.02). Men younger than 55 years carrying risk alleles for both genes (p21 Ser31Arg and TP53 Arg72Pro) had an increased risk (adjusted OR 5.78; 95% CI 1.38-24.19), as did smokers with both risk alleles (adjusted OR 4.52; 95% CI 1.52-13.50). CONCLUSION: The presence of both variant alleles increased the risk of developing lung cancer in men, particularly in smokers younger than 55 years.
BACKGROUND: The aim of this study was to investigate how Ser31Arg polymorphisms in p21 may modify lung cancer susceptibility. Because p21 is the major downstream mediator of p53, we analyzed the combined effect of two polymorphisms, p21 Ser31Arg and TP53 Arg72Pro, to elucidate whether polymorphic variants determine the risk of lung cancer. METHODS: This was designed as a hospital-based case-control study, and included 675 cases and 675 control subjects matched by ethnicity, gender, and age. Genotypes were determined by polymerase chain reaction restriction fragment length polymorphism, and multivariate unconditional logistic regression was performed to analyze the results. RESULTS: Subjects who carried the p21 Ser31Arg allele had a higher risk of lung cancer (adjusted odds ratio [OR] 1.38; 95% confidence interval [CI] 0.99-2.03). This risk was increased in men aged younger than 55 years (adjusted OR 2.35; 95% CI 1.00-5.51). Smokers had an increased risk of lung cancer (adjusted OR 2.23; 95% CI 1.24-4.02). Men younger than 55 years carrying risk alleles for both genes (p21 Ser31Arg and TP53 Arg72Pro) had an increased risk (adjusted OR 5.78; 95% CI 1.38-24.19), as did smokers with both risk alleles (adjusted OR 4.52; 95% CI 1.52-13.50). CONCLUSION: The presence of both variant alleles increased the risk of developing lung cancer in men, particularly in smokers younger than 55 years.
Authors: Yi Young Choi; Hyo-Kyung Kang; Jin Eun Choi; Jin Sung Jang; Eun Jin Kim; Sung Ick Cha; Won Kee Lee; Sin Kam; Chang Ho Kim; Sung Beom Han; Tae Hoon Jung; Jae Yong Park Journal: J Hum Genet Date: 2007-11-28 Impact factor: 3.172
Authors: D Feskanich; R G Ziegler; D S Michaud; E L Giovannucci; F E Speizer; W C Willett; G A Colditz Journal: J Natl Cancer Inst Date: 2000-11-15 Impact factor: 13.506
Authors: Brenda L Powell; Iris L van Staveren; Paul Roosken; Fabienne Grieu; Els M J J Berns; Barry Iacopetta Journal: Carcinogenesis Date: 2002-02 Impact factor: 4.944
Authors: Patricia González-Arriaga; M Felicitas López-Cima; Ana Fernández-Somoano; Teresa Pascual; Manuel G Marrón; Xose S Puente; Adonina Tardón Journal: BMC Cancer Date: 2008-12-19 Impact factor: 4.430
Authors: M Felicitas López-Cima; Patricia González-Arriaga; Laura García-Castro; Teresa Pascual; Manuel G Marrón; Xose S Puente; Adonina Tardón Journal: BMC Cancer Date: 2007-08-16 Impact factor: 4.430